Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-11-21

FDA Approved: NABUMETONE — Supplemental Application (Chartwell RX, LLC)

View source ↗

Summary

FDA has approved a supplemental application for NABUMETONE submitted by Chartwell RX, LLC. The action updates an existing approved ANDA for nabumetone.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nabumetone (Nabumetone)

Snippet

SUPPL AP for NABUMETONE (NABUMETONE)